BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gu M, Zhang S, Zhao Y, Huang J, Wang Y, Li Y, Fan S, Yang L, Ji G, Tong Q, Huang C. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. Pharmacol Res 2017;121:22-32. [PMID: 28428116 DOI: 10.1016/j.phrs.2017.04.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Yu Y, Zhou L, Yang Y, Liu Y. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med 2018;16:2175-82. [PMID: 30186456 DOI: 10.3892/etm.2018.6501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yu Y, Wu J, Li J, Liu Y, Zheng X, Du M, Zhou L, Yang Y, Luo S, Hu W, Li L, Yao W, Liu Y. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother 2020;128:110304. [PMID: 32497865 DOI: 10.1016/j.biopha.2020.110304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cheng L, Zhang H, Liang H, Sun X, Shen X, Wang J, Wang W, Yuan Q, Ri H, Kim T, Kang M, Linhardt RJ. Enzymatic Bioconversion of Cycloastragenol-6-O-β-D-glucoside into Cycloastragenol by a Novel Recombinant β-Glucosidase from Phycicoccus sp. Soil748. Process Biochemistry 2020;90:81-8. [DOI: 10.1016/j.procbio.2019.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wei Y, Lu Y, Zhu Y, Zheng W, Guo F, Yao B, Xu S, Wang Y, Jin L, Li Y. Structural basis for the hepatoprotective effects of antihypertensive 1,4-dihydropyridine drugs. Biochim Biophys Acta Gen Subj 2018;1862:2261-70. [PMID: 30048741 DOI: 10.1016/j.bbagen.2018.07.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Wang J, Wu M, Cao S, Cai H, Zhao Z, Song Y. Cycloastragenol ameliorates experimental heart damage in rats by promoting myocardial autophagy via inhibition of AKT1-RPS6KB1 signaling. Biomedicine & Pharmacotherapy 2018;107:1074-81. [DOI: 10.1016/j.biopha.2018.08.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
6 Zheng P, Ding Y, Lu F, Liu N, Wu H, Bian Z, Chen X, Yang D. Atorvastatin reverses high cholesterol-induced cardiac remodelling and regulates mitochondrial quality-control in a cholesterol-independent manner: An experimental study. Clin Exp Pharmacol Physiol 2021;48:1150-61. [PMID: 33891707 DOI: 10.1111/1440-1681.13507] [Reference Citation Analysis]
7 Zhu X, Cao Y, Su M, Chen M, Li C, Yi, Qin J, Tulake W, Teng F, Zhong Y, Tang W, Wang S, Dong J. Cycloastragenol alleviates airway inflammation in asthmatic mice by inhibiting autophagy. Mol Med Rep 2021;24:805. [PMID: 34542166 DOI: 10.3892/mmr.2021.12445] [Reference Citation Analysis]
8 Leng YR, Zhang MH, Luo JG, Zhang H. Pathogenesis of NASH and Promising Natural Products. Chin J Nat Med 2021;19:12-27. [PMID: 33516448 DOI: 10.1016/S1875-5364(21)60002-X] [Reference Citation Analysis]
9 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
10 Li M, Li SC, Dou BK, Zou YX, Han HZ, Liu DX, Ke ZJ, Wang ZF. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin 2020;41:1025-32. [PMID: 32203080 DOI: 10.1038/s41401-020-0386-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
12 Gitto S, Guarneri V, Sartini A, Andreone P. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Expert Rev Gastroenterol Hepatol 2018;12:165-71. [PMID: 29082798 DOI: 10.1080/17474124.2018.1399060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li Y, Chen H, Ke Z, Huang J, Huang L, Yang B, Fan S, Huang C. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice. Biochemical and Biophysical Research Communications 2020;521:639-45. [DOI: 10.1016/j.bbrc.2019.10.169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Wu J, Zeng Z, Li Y, Qin H, Zuo C, Zhou C, Xu D. Cycloastragenol protects against glucocorticoid-induced osteogenic differentiation inhibition by activating telomerase. Phytother Res 2021;35:2034-44. [PMID: 33165990 DOI: 10.1002/ptr.6946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Al Sharif M, Alov P, Vitcheva V, Diukendjieva A, Mori M, Botta B, Tsakovska I, Pajeva I. Natural modulators of nonalcoholic fatty liver disease: Mode of action analysis and in silico ADME-Tox prediction. Toxicology and Applied Pharmacology 2017;337:45-66. [DOI: 10.1016/j.taap.2017.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yue SJ, Liu J, Feng WW, Zhang FL, Chen JX, Xin LT, Peng C, Guan HS, Wang CY, Yan D. System Pharmacology-Based Dissection of the Synergistic Mechanism of Huangqi and Huanglian for Diabetes Mellitus. Front Pharmacol 2017;8:694. [PMID: 29051733 DOI: 10.3389/fphar.2017.00694] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 12.8] [Reference Citation Analysis]
17 Qiu R, Luo G, Li X, Zheng F, Li H, Zhang J, You Q, Xiang H. Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study. Bioorganic & Medicinal Chemistry Letters 2018;28:2879-84. [DOI: 10.1016/j.bmcl.2018.07.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Chen M, Xie Y, Gong S, Wang Y, Yu H, Zhou T, Huang F, Guo X, Zhang H, Huang R, Han Z, Xing Y, Liu Q, Tong G, Zhou H. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res 2021;172:105849. [PMID: 34450307 DOI: 10.1016/j.phrs.2021.105849] [Reference Citation Analysis]
19 De Marino S, Festa C, Sepe V, Zampella A. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 137-65. [DOI: 10.1007/164_2019_237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
20 Yang X, Gonzalez FJ, Huang M, Bi H. Nuclear receptors and non-alcoholic fatty liver disease: An update. Liver Research 2020;4:88-93. [DOI: 10.1016/j.livres.2020.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]